| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,268 | 2,372 | 18.11. | |
| 2,292 | 2,348 | 18.11. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | ORYZON GENOMICS, S.A.: Call of the Extraordinary General Shareholders' Meeting of Oryzon Genomics, S.A. | 2 | CNMV | ||
| 10.11. | Oryzon Genomics, S.A.: ORYZON Reports Third Quarter 2026 Financial Results and Provides Corporate Update | 1 | GlobeNewswire (USA) | ||
| 04.11. | Oryzon Genomics, S.A.: ORYZON to Present Updated Positive Clinical Data for Iadademstat in Hematological Malignancies at ASH 2026 | 5 | GlobeNewswire (USA) | ||
| 15.10. | Oryzon Genomics, S.A.: ORYZON further strengthens vafidemstat's patent portfolio with new decisions to grant | 2 | GlobeNewswire (USA) | ||
| 07.10. | Oryzon Genomics: AML-Wirkstoff Iadademstat zeigt vielversprechendes Potenzial | 4 | Investing.com Deutsch | ||
| 10.09. | Oryzon Genomics, S.A.: ORYZON to Participate in Upcoming Events in September and October | 2 | GlobeNewswire (USA) | ||
| 27.07. | Oryzon Genomics, S.A.: ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026 | 548 | GlobeNewswire (Europe) | Positive clinical data presented at EHA for iadademstat in first line acute myeloid leukemia (AML); iadademstat+azacitidine+venetoclax resulted in 100% ORR, 89% CRc and 78% CR, including in patients... ► Artikel lesen | |
| ORYZON GENOMICS Aktie jetzt für 0€ handeln | |||||
| 08.07. | Oryzon Genomics, S.A.: ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD) | 472 | GlobeNewswire (Europe) | Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPDU.S. patent to expire in March 2043, including 1,095 days of Patent Term AdjustmentNotice of allowance also received... ► Artikel lesen | |
| 01.07. | ORYZON GENOMICS, S.A.: ORYZON announces the voting results from its Ordinary General Shareholders' Meeting | 1 | CNMV | ||
| 01.07. | Oryzon Genomics, S.A.: ORYZON Raises €12 Million and Signs a Financing Agreement with COFIDES to Strengthen its Balance Sheet and Accelerate its Clinical Programs | 466 | GlobeNewswire (Europe) | Issued 4,444,445 new ordinary shares Priced at €2.70 per share, representing a 14.15% discount on the five-day VWAP and a 12.68% discount to the June 30 closing priceThe transaction has been structured... ► Artikel lesen | |
| 11.06. | ORYZON GENOMICS, S.A.: ORYZON presents updated positive clinical data for iadademstat in AML at the European Hematology Association (EHA) Congress | 4 | CNMV | ||
| 14.05. | Oryzon Genomics, S.A.: ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026 | 906 | GlobeNewswire (Europe) | Updated positive data from iadademstat in 1L AML unfit patients to be presented at EHA, with 100% ORR, 93% CRc and 79% strict CR at abstract submission cut-offPositive updated data from iadademstat... ► Artikel lesen | |
| 25.03. | Oryzon Genomics, S.A.: ORYZON Strengthens Vafidemstat Patent Portfolio With U.S. Notice of Allowance | 562 | GlobeNewswire (Europe) | Covers the use of vafidemstat for treating non-aggressive symptoms of Borderline Personality Disorder (BPD) MADRID, and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN... ► Artikel lesen | |
| 23.03. | Oryzon Genomics, S.A.: ORYZON Announces U.S. Patent Grant Covering Iadademstat Combinations with Venetoclax | 602 | GlobeNewswire (Europe) | Key combination for the treatment of first-line AMLRecent data from an ongoing study in first-line AML showed a 100% overall response rate (ORR) with iadademstat in combination with venetoclax and... ► Artikel lesen | |
| 10.03. | Oryzon Genomics - Refreshed outlook with near-term catalysts | 641 | Edison Investment Research | We update our investment view on Oryzon Genomics following the company's FY25 results and refreshed profile. This includes an array of near-term milestones for iadademstat, lead asset for oncological-... ► Artikel lesen | |
| 27.02. | Oryzon Genomics, S.A.: ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025 | 890 | GlobeNewswire (Europe) | Strong cash position at year-end 2025: $33.3 million (€28.4 million) CNS(Vafidemstat) Appointed renowned Rolando Gutierrez-Esteinou, M.D. as new CMO for CNSPreparing protocol resubmission to incorporate... ► Artikel lesen | |
| 22.12.25 | Oryzon Genomics, S.A.: ORYZON Expands Global Patent Protection for Iadademstat with Grant Decision in Japan Covering Combinations with PD-1/PD-L1 Inhibitors | 492 | GlobeNewswire (Europe) | MADRID and CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today... ► Artikel lesen | |
| 15.12.25 | Oryzon Genomics, S.A.: ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders' Meeting | 581 | GlobeNewswire (Europe) | 37.8% of voting rights present or representedAll resolutions were approved MADRID and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 76,60 | -0,07 % | BioNTech-Aktie: Totes Kapital? | Die Aktie von BioNTech bleibt trotz des rückläufigen Impfstoffgeschäfts ein spannender Titel am Aktienmarkt. Anleger richten ihren Blick zunehmend auf die milliardenschwere Forschungspipeline im Bereich... ► Artikel lesen | |
| EVOTEC | 2,728 | -0,80 % | Evotec-Aktie: Gewinn- und Umsatzrekord? | Die Aktie des Hamburger Wirkstoffforschers Evotec bleibt ein spannender, aber risikoreicher Titel am deutschen Aktienmarkt. Nach schwierigen Monaten sorgen erste operative Fortschritte, neue Partnerschaften... ► Artikel lesen | |
| MEDIGENE | 0,003 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| QIAGEN | 45,200 | 0,00 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| MODERNA | 179,14 | -0,08 % | Ihre wichtigsten Termine: Heute im Blickpunkt: Moderna, DocMorris, Applied Materials, Siemens und Cisco | © Foto: Bodo Schackow/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte: DE0008404005... ► Artikel lesen | |
| AMGEN | 405,10 | +0,19 % | Argus raises Amgen stock price target on pipeline strength | ||
| VALNEVA | 2,411 | -1,23 % | Valneva-Aktie über der 50-Tage-Linie: Positive Shigella-Daten treiben an | ||
| EPIGENOMICS | 0,870 | 0,00 % | PTA-PVR: Epigenomics AG: Veröffentlichung nach § 40 Abs. 1 WpHG | DJ PTA-PVR: Epigenomics AG: Veröffentlichung nach § 40 Abs. 1 WpHG
Veröffentlichung gem. -- 40 Abs. 1 WpHG
Epigenomics AG: Veröffentlichung nach -- 40 Abs. 1 WpHG
Heidelberg (pta000/26.10.2026/15:00... ► Artikel lesen | |
| NOVAVAX | 7,180 | -0,97 % | Novavax: Warum der Zahlen-Erfolg nicht alle überzeugt | ||
| STRYKER | 290,10 | +0,07 % | General Dynamics wins $332.5M Army contract for Stryker support | ||
| BIOGEN | 227,05 | -0,85 % | Biogen Reports Two-Year Data Showing Continued Benefit Of Dianersen In Early Alzheimer's Disease | WESTON (dpa-AFX) - Biogen (BIIB) presented new Phase 2 data showing that diranersen, an investigational therapy targeting the tau protein, continued to slow disease progression in people with... ► Artikel lesen | |
| BIOFRONTERA | 2,820 | -3,09 % | Biofrontera AG: Liquidität unter Druck - was jetzt zählt | ||
| HEIDELBERG PHARMA | 2,010 | -1,47 % | Formycon, Heidelberg Pharma und Medios: Drei Biotech-Nebenwerte, drei völlig unterschiedliche Signale - Formycon hat die Analysten auf seiner Seite | ||
| ILLUMINA | 191,14 | -0,07 % | Illumina Stock Outlook: Is Wall Street Bullish or Bearish? | ||
| SUMMIT THERAPEUTICS | 10,500 | 0,00 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence |